OOIR: Observatory of International Research

Papers

(The H4-Index of Value in Health is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Author Reply	115
When Do Value-Based Contracts Add Value? Insights From Probabilistic Simulations	77
Table of Contents	75
EE237 The Risk-Based Price: Incorporating Uncertainty and Risk Attitues in Health Technology Pricing	74
HSD101 Lack of concordance between real-world treatment patterns and clinical guideline recommendations for metastatic hormone-sensitive prostate cancer (mhspc) patients	71
RWD48 Inpatient Resource Utilization Outcomes Among Patients Living with Fragile X Syndrome and Comorbid Autism Spectrum Disorder in the US	70
Editorial Board	67
P32 Power Implications of Estimator Choice in Synthetic Control Arm Analyses: Results from a Simulation Comparing Average Treatment Effects on the Treated and Untreated Under Propensity Score Weightin	67
HSD129 Managing Members with Complex Conditions: A Blue Cross and Blue Shield of Louisiana Program Evaluation	66
RWD86 Healthcare Resource Utilization and Economic Burden of Patients with Gout in the United States	62
HTA35 Testing and Piloting of a Value Framework for Diagnostic Technologies in Latin America	60
EE467 Recovid Study. Cost-Effectivness Analysis of Using Nutridrink 200 ML in the Treatment of COVID-19 in the Hospital	58
RWD116 Reduced Lysosomal Acid Lipase Activity in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Current Evidence and Future Directions	54
EE498 Economic Burden of Interstitial Lung Disease in a Commercially Insured Population with Sjogren's Syndrome in the United States	50
RWD120 Impact of Healthcare Fragmentation on Survival of Patients with Colorectal Cancer in Colombia	50
EPH139 COVID-19 Vaccine Related Adverse Events in a Population Aged 5–17 Years: A Study of Reports from the VAERS Database	49
HTA49 Determining Appropriate Health Economic Modeling Approaches in Fabry Disease	49
RWD118 Rapid Diversification of Immune Checkpoint Inhibitor Usage in Community Health Systems in the US Following New Drug Approvals	47
HTA48 Minimum Follow-up Time Required for the Detection of the Impact of Treatments on Neuropathic Pain and Gastrointestinal Complaints in Fabry Disease	46
RWD140 Using Machine Learning to Identify Non-Metastatic Castration-Resistant Prostate Cancer (NMCRPC) Patients from Electronic Health Record Data	45
HTA70 Forecasting Drug Price for Reimbursement By Utilizing a Value-Price Relationship, a Case Study in Hormone-Relapsed Prostate Cancer	45
RWD142 Clinical Characteristics of Chinese Patients with Psoriasis Receiving Interleukin-17A Inhibitors: A Single-Center Retrospective Analysis	44
EPH23 Sociodemographic and Clinical Characteristics of Patients with Atopic Dermatitis in Colombia:Preliminary Results of Rendac	43
SA11 Data Visualization: A Tool to Enhance the Interpretability of Complex and Dense Data Sources	41
PCR71 Health State Utilities in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Pembrolizumab Plus Axitinib or Sunitinib	37

EPH158 Years of Life Lost Due to Diabetes Mellitus in Colombia, 1979-2017	36
SA40 Indexing Regulatory Documents and Clinical Evidence Publications for Non-Small Cell Lung Cancer (NSCLC) Therapeutics: Establishing a Dataset to Enable the Study of Endpoint Fidelity	36
PCR68 Patient-Provider Communication and Health-Related Quality of Life Among Individuals with Chronic Obstructive Pulmonary Disease in the United States	36
EE279 A Systematic Literature Review of the Economic Burden in Patients with Myelodysplastic Syndrome	35
EPH61 Comparing Fibrosis Staging Approaches Among Patients with Non-Alcoholic Steatohepatitis (NASH) Using Real World Data (RWD)	34
EPH69 Cancers Treatment from Their Perspective: A Qualitative Pilot Study Exploring the Knowledge Attitude and Practice of Folk Medicine Practitioners in a Low-and-Middle-Income-Country	33
EE303 Estimating Recurrences Prevented and Costs Avoided with Atezolizumab in Early Non-Small Cell Lung Cancer in the United States	33
PCR102 Leveraging Social Media for Patient Experience Insights in Rare Disease	33
PCR101 Item Response Theory Analysis of the Ilqi	33
EPH67 Comparisons of Twenty-Year Trends in Direct Costs, Absence Payments and Lost Time for Employee "Caregivers” of Patients with Breast, Skin, GI, Female, Male, and "Other” Cancers	33
EE302 Households Out-of-Pocket Healthcare Expenditures Based on Number of Chronic Conditions in Riyadh, Saudi Arabia: A Quantile Regression Approach	33